Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Research output: Contribution to journal › Journal article › Research › peer-review
The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
| Original language | English |
|---|---|
| Journal | Lancet |
| Volume | 380 |
| Issue number | 9856 |
| Pages (from-to) | 1829-39 |
| Number of pages | 11 |
| ISSN | 0140-6736 |
| DOIs | |
| Publication status | Published - 2012 |
ID: 48584402